famotidine has been researched along with Respiratory Tract Infections in 1 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Respiratory Tract Infections: Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hogan Ii, RB | 1 |
| Hogan Iii, RB | 1 |
| Cannon, T | 1 |
| Rappai, M | 1 |
| Studdard, J | 1 |
| Paul, D | 1 |
| Dooley, TP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) to Evaluate the Safety and Efficacy of Drug Combinations in COVID-19 Patients[NCT05077332] | Phase 2 | 2,000 participants (Anticipated) | Interventional | 2021-12-29 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for famotidine and Respiratory Tract Infections
| Article | Year |
|---|---|
Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Betacoronavirus; Cetirizine; Cohort Studies; Coronavirus | 2020 |